Paper Review Records
All Paper Review Records
27 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Drug–Drug Interaction Assessment of WXFL10203614 With Rifampicin, Itraconazole and Metformin: A Three‐Cohort Phase I Study
Jinmei Zhou; Mengshuang Gao; Daolei Zhou; Zhiwei Zhang; Huan Zhang; Yu Sun; Huan ZhouShow moreShow less
1. School of Pharmacy Bengbu Medical University Bengbu Anhui China; 2. Clinical Trial Center The First Affiliated Hospital of Bengbu Medical University Bengbu Anhui China; 3. College of Laboratory Medicine Bengbu Medical University Bengbu Anhui China; 4. Zhuohe Pharmaceutical Group Co., Ltd. Wuxi City Jiangsu Province ChinaShow moreShow less
Comparability of Pharmacokinetics, Safety, and Tolerability of Canakinumab Administration With One Injection (200 mg) of Pre‐Filled Syringe or Auto‐Injector Versus Two Injections (150 and 50 mg) of Pre‐Filled Syringe in Healthy Subjects
Abhijit Chakraborty; Anshu Marathe; Jong Bong Lee; Kari Wiedinger; Britta Zehnpfennig; Carole Schuhler; Simantini Eddy; Michelle QuinlanShow moreShow less
1. Novartis Institutes for Biomedical Research East Hanover NJ USA; 2. Insmed NJ USA; 3. Novartis Pharma AG Basel Switzerland; 4. Novartis Pharmaceuticals Corporation East Hanover NJ USAShow moreShow less
A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants
Joseph F. Grippo; Anja Pfaff; Zhongli Xu; Isabell Otto; Claus Thielert; Mihaly Imre; Rui Liu; Wantanee Phuapradit; Yazhong Pei; Cuie Chen; Maria Habel; Renfeng Guo; Camilla ChongShow moreShow less
1. InflaRx GmbH Jena Germany; 2. InflaRx Pharmaceuticals, Inc. Ann Arbor MI USAShow moreShow less
A Bioequivalence Study of Two Formulations of Enzalutamide Soft Capsules in Healthy Chinese Male Subjects
Jianxin Wang; Kai Gu; Mingxuan Zhang; Miao Yu; Pei Zhao; Jing Yu; Xiaohong Guo; Yating Bai; Jie Liu; Xiaoli Wang; Xiaolai YangShow moreShow less
1. School of pharmacy Ningxia Medical University Yinchuan Ningxia Hui Autonomous Region China; 2. Department of Pharmacy Gansu Provincial People's Hospital Lanzhou Gansu Province China; 3. Faculty of Health Sciences (FHS) University of Macau Taipa Macau SAR ChinaShow moreShow less
When Clinical Pharmacology Cannot Wait for Complete Data: Reflections Following the 2026 ACCP Annual Meeting
Amalia M. IssaShow moreShow less
1. Editor‐in‐Chief, Clinical Pharmacology in Drug Development USAShow moreShow less
Fed–Fasted Differences in Clindamycin Hydrochloride Capsule Pharmacokinetics: A Pooled Analysis of Publicly Available China CDE Regulatory Summaries
Rui Li; Deshuang Yang; Lang Zhao; Zhengyi Cao; Xiaoyu Li; Mengxi YangShow moreShow less
1. Department of Geriatrics China‐Japan Friendship Hospital Chaoyang District Beijing China; 2. Department of Cardiology of Integrated traditional Chinese and Western Medicine China‐Japan Friendship Hospital Chaoyang District Beijing China; 3. Department of Emergency China‐Japan Friendship Hospital Chaoyang District Beijing China; 4. Department of Hematology China‐Japan Friendship Hospital Chaoyang District Beijing China; 5. Jinan Academician Workstation, Shandong Academy of Chinese Medicine, Lixia District Jinan City Shandong Province ChinaShow moreShow less
FAQ
How long does Clinical Pharmacology in Drug Development take to review a manuscript?
As of 2026-11-17, CrushSCI has 27 complete review records for Clinical Pharmacology in Drug Development. The fastest paper went from submission to acceptance in 2 days (When Clinical Pharmacology Cannot Wait for Complete Data: Reflections Following the 2026 ACCP Annual Meeting, received 2026-09-28, accepted 2026-09-30); the slowest took 296 days. The average is 125.7 days and the median is 111 days. The fastest record has an unusually short interval; please check the original source.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
